Tsinghua-run incubator Lotus Lake Capital has backed Insight Lifetech, which develops treatment and diagnostic tools for coronary heart disease.
China-based medical device manufacturer Insight Lifetech has procured RMB200m ($28.4m) of series B-plus funding from investors including Lotus Lake Capital, an incubator run by Tsinghua University, according to DealStreetAsia.
The round was led by SDIC Gaoxin Industrial Investment, an investment arm of state-owned investment holding group State Development and Investment, and also included Green Pine Capital Partners, Efung Capital, Sequoia Capital China and Sherpa Venture Partners.
Founded in 2015, Insight Lifetech develops medical device-based treatments and diagnostic tools for coronary heart disease.
The company’s pipeline includes cardiovascular imaging systems and catheters as well as intravenous ultrasound technology classified as high-priority by Chinese regulators.
Insight completed a $14m series B round in 2018 that featured both Sequoia China and Sherpa Venture Partners.
The company’s earlier funding came from implantable medical devices producer Sibionics, Decheng Capital and TigerYeah Capital, DealStreetAsia said.
